Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 30Neoplasms 16Lung Neoplasms 3Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pleural Effusion 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Genital Neoplasms, Female 1Fatigue 1Carcinoma 1

Interventions

Carboplatin 31Cisplatin 24pembrolizumab 23Pemetrexed 21Paclitaxel 21Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × Darbepoetin alfa × Clear all
NCT00989092 2014-01-29

Darbepoetin Alfa and Anemia of Cancer

Amgen

Phase 2 Terminated
287 enrolled 21 charts
Classical hematology

Anemia, Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡